NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018
- PMID: 28982745
- DOI: 10.6004/jnccn.2017.0157
NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018
Abstract
Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thrombohemorrhagic complications and a high risk of transformation to MF and acute myeloid leukemia. The diagnosis and management of PV and ET has evolved since the identification of mutations implicated in their pathogenesis. These NCCN Guideline Insights discuss the recommendations outlined in the NCCN Guidelines for the risk stratification, treatment, and special considerations for the management of PV and ET.
Copyright © 2017 by the National Comprehensive Cancer Network.
Similar articles
-
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw. 2022 Sep;20(9):1033-1062. doi: 10.6004/jnccn.2022.0046. J Natl Compr Canc Netw. 2022. PMID: 36075392
-
Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.BMC Cancer. 2016 Feb 27;16:167. doi: 10.1186/s12885-016-2208-2. BMC Cancer. 2016. PMID: 26922064 Free PMC article.
-
[Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].Vnitr Lek. 2011 Feb;57(2):189-213. Vnitr Lek. 2011. PMID: 21416861 Review. Czech.
-
Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions.Ann Hematol. 2022 May;101(5):935-951. doi: 10.1007/s00277-022-04826-7. Epub 2022 Mar 28. Ann Hematol. 2022. PMID: 35344066 Review.
-
Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.Acta Haematol. 2015;133(1):36-51. doi: 10.1159/000358580. Epub 2014 Aug 7. Acta Haematol. 2015. PMID: 25116092 Review.
Cited by
-
"Y appearance" infarction: caused by essential thrombocythemia.Thromb J. 2024 Oct 7;22(1):88. doi: 10.1186/s12959-024-00656-x. Thromb J. 2024. PMID: 39375672 Free PMC article.
-
The triple A (AAA) model globally recapitulates adverse outcomes in essential thrombocythemia.Blood Cancer J. 2024 Oct 1;14(1):169. doi: 10.1038/s41408-024-01151-2. Blood Cancer J. 2024. PMID: 39353890 Free PMC article. No abstract available.
-
Impact of Phlebotomy on Quality of Life in Low-Risk Polycythemia Vera.J Clin Med. 2024 Aug 22;13(16):4952. doi: 10.3390/jcm13164952. J Clin Med. 2024. PMID: 39201091 Free PMC article. Review.
-
Spinal extramedullary hematopoiesis mimicking an epidural tumor in a patient with high-risk polycythemia vera: illustrative case.J Neurosurg Case Lessons. 2024 Jul 8;8(2):CASE23659. doi: 10.3171/CASE23659. Print 2024 Jul 8. J Neurosurg Case Lessons. 2024. PMID: 38976913 Free PMC article.
-
Etiologies of Splenic Venous Hypertension: A Review.J Clin Transl Hepatol. 2024 Jun 28;12(6):594-606. doi: 10.14218/JCTH.2024.00054. Epub 2024 May 20. J Clin Transl Hepatol. 2024. PMID: 38974953 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
